Skip to main content

Table 5 Clinical trials testing combined targeting strategies of more than 1 checkpoint receptor

From: Reactivation of dormant anti-tumor immunity – a clinical perspective of therapeutic immune checkpoint modulation

Drug target

(Synonym)

Compound

(Synonym)

Status

Indication

ClinicalTrials.gov

identifier

CD134 (OX40)

CD137 (ILA, 4-IBB)

PF-04518600

Utomilumab (PF-05082566)

Phase I

Neoplasms

NCT02315066

CD134 (OX40)

CD137 (ILA, 4-IBB)

CD274 (PDL1)

PF-04518600

Utomilumab (PF-05082566)

Avelumab (MSB-0010718C)

Phase I

Neoplasms

NCT02554812

CD137 (ILA, 4-IBB)

CD279 (PD1)

PF-05082566

MK-3475

Phase I

Advanced solid tumors

NCT02179918

CD123 (OX40)

CD274 (PDL1)

VEGF

MOXR0916

Atezolizumab (MPDL-3280A)

Bevacizumab

Phase I

Advanced or metastatic solid tumors

NCT02410512

CD134 (OX40)

CD152 (CTLA4)

CD274 (PDL1)

MEDI-0562

Tremelimumab (CP-675,206)

Durvalumab (MEDI-4736)

Phase I

Advanced or metastatic solid tumors

NCT02705482

CD134 (OX40)

CD152 (CTLA4)

CD274 (PDL1)

MEDI-6469

Tremelimumab (CP-675,206)

Durvalumab (MEDI-4736)

Phase I/II

Advanced solid tumors or DLBCL

NCT02205333

CD252 (OX40L)

CD274 (PDL1)

MEDI-6383

Durvalumab (MEDI-4736)

Phase I

Recurrent or metastatic solid tumors

NCT02221960

CD276 (B7-H3)

CD152 (CTLA4)

Enoblituzumab (MGA-271)

Ipilimumab

Phase I

B7-H3 expressing solid tumors

NCT02381314

CD276 (B7-H3)

CD279 (PD1)

Enoblituzumab (MGA-271)

Pembrolizumab

Phase I

B7-H3 expressing solid tumors

NCT02475213

VISTA

CD274 (PDL1)

CA-170

(AUPM-170)

Phase I

Advanced solid tumors or lymphomas, non-responsive to available therapies

NCT02812875

CD152 (CTLA4)

CD274 (PDL1)

Cytotoxic

Tremelimumab (CP-675,206)

Durvalumab (MEDI-4736)

Chemotherapy

Phase I

Phase I

Phase I

Resectable CRC with liver metastases

Solid malignancies

Multiple Myeloma

NCT02754856

NCT02537418

NCT02716805

CD152 (CTLA4)

CD274 (PDL1)

Cytotoxic

Tremelimumab (CP-675,206)

Durvalumab (MEDI-4736)

Radiotherapy

Phase I

Phase II

Phase II

Unresectable pancreatic cancer

NSCLC, CRC

Relapsed SCLC

NCT02311361

NCT02888743

NCT02701400

CD152 (CTLA4)

CD274 (PDL1)

Tremelimumab (CP-675,206)

Durvalumab (MEDI-4736)

Phase I

Phase II

Phase II

Phase II

Phase III

Advanced solid tumors

Unresectable hepatocellular carcinoma

Metastatic Her2 negative breast cancer

Head and neck cancer

NSCLC

NCT02261220

NCT02519348

NCT02536794

NCT02319044

NCT02453282

CD274 (PDL1)

CD279 (PD1)

Durvalumab (MEDI-4736)

MEDI-0680

Phase I/II

Advanced malignancies

NCT02118337

CD137 (ILA, 4-IBB)

CD279 (PD1)

Urelumab

Nivolumab (BMS-936558)

Phase I

Phase II

Recurrent glioblastoma

Cisplatin-ineligible bladder carcinoma

NCT02658981

NCT02845323

CD152 (CTLA4)

CD137 (ILA, 4-IBB)

Ipilimumab

BMS-663513

Phase I

Advanced melanoma

NCT00803374

CD223 (LAG3)

CD279 (PD1)

BMS-986016

Nivolumab (BMS-936558)

Phase I

Relapsed hematologic malignancies

NCT02061761

CD366 (TIM3)

CD279 (PD1)

MBG-453

PDR-001

Phase I/II

Advanced malignancies

NCT02608268

CD279 (PD1)

CD357 (GITR)

PDR-001

GWN-323

Phase I/II

Advanced malignancies and lymphomas

NCT02740270

CD279 (PD1)

CD223 (LAG3)

PDR-001

LAG-525

Phase I/II

Advanced malignancies

NCT02460224

CD357 (GITR)

CD279 (PD1)

MK-4166

Pembrolizumab (MK-3475)

Phase I

Advanced solid tumors

NCT02132754

  1. DLBCLindicates diffuse large B-cell lymphoma, CRC colorectal cancer, NSCLC non small cell lung cancer, SCLC small cell lung cancer, MRCC metastatic renal cell carcinoma